Last update Sept. 4, 2022

クレボプリド

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a prokinetic from the benzamide group, a dopamine antagonist and similar to Metoclopramide, but with higher extrapyramidal side-effects (Serrano 1999, Cuena 1998, Jiménez 1996) and poorly known pharmacokinetics. It is used to treat nausea, vomiting, and other gastrointestinal disorders. Oral administration three times a day, or intravenously.

At latest update, relevant published data on excretion into breast milk were not found.

The scarcity of known pharmacokinetic data does not allow to predict the magnitude of its possible excretion in breast milk.

As with Metoclopramide it can produce increased secretion of Prolactin and galactorrhea. (AEMPS 2014, Perez 1980)

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

Alternatives

  • Domperidone ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metoclopramide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

クレボプリド is Clebopride in Japanese.

Is written in other languages:

クレボプリド is also known as

Groups

クレボプリド belongs to these groups or families:

Tradenames

Main tradenames from several countries containing クレボプリド in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 374 daltons
pKa 14.61 -
Tmax 1 - 2 hours

References

  1. AEMPS. Cleboprida. Ficha técnica. 2014 Full text (in our servers)
  2. Serrano Serrano ME, Alvarez Frejo M, Tabernero García J, Martín Martín S. Síndrome extrapiramidal por cleboprida. \ [An extrapyramidal syndrome due to clebopride]. Aten Primaria. 1999 Abstract Full text (link to original source) Full text (in our servers)
  3. Cuena Boy R, Maciá Martínez MA. Toxicidad extrapiramidal a metoclopramida y a cleboprida: estudio de las notificaciones voluntarias de reacciones adversas al Sistema Español de Farmacovigilancia. \ [Extrapyramidal toxicity caused by metoclopramide and clebopride: study of voluntary notifications of adverse effects to the Spanish Drug Surveillance System]. Aten Primaria. 1998 Abstract Full text (link to original source) Full text (in our servers)
  4. Jiménez-Jiménez FJ, Ortí-Pareja M, Ayuso-Peralta L, Gasalla T, Cabrera-Valdivia F, Vaquero A, Tejeiro J, García-Albea E. Drug-induced parkinsonism in a movement disorders unit: A four-year survey. Parkinsonism Relat Disord. 1996 Abstract
  5. Perez-Lopez FR, Legido A, Sisskin M, Abos MD. Stimulatory effect of clebopride on human prolactin secretion. Fertil Steril. 1980 Abstract

Total visits

83

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM